U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C47H74O19
Molecular Weight 943.0791
Optical Activity UNSPECIFIED
Defined Stereocenters 26 / 26
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DESLANOSIDE

SMILES

[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O[C@]4([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]5CC[C@@]6(C)[C@]([H])(CC[C@]7([H])[C@]6([H])C[C@@H](O)[C@]8(C)[C@H](CC[C@]78O)C9=CC(=O)OC9)C5

InChI

InChIKey=OBATZBGFDSVCJD-LALPQLPRSA-N
InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1

HIDE SMILES / InChI

Description

Deslanoside is a cardiotonic glycoside from the leaves of Digitalis lanata. It is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). It also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
41.3 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CEDILANID-D
Primary
CEDILANID-D

T1/2

ValueDoseCo-administeredAnalytePopulation
36 h
1.6 mg unknown, intravenous
DESLANOSIDE serum
Homo sapiens

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Intravenous
In Vitro Use Guide
Deslanoside produced significant stimulatory effects (45.3% ± 4.0% vs 87.0% ± 7.8%, P < 0.01) on the contractility of rat jejunal smooth muscle fragment (JSMF) in the low contractile states, and produced significant inhibitory effects (180.6% ± 17.8% vs 109.9% ± 10.8%, P < 0.01) on the contractility of rat JSMF in the high contractile states.